论文部分内容阅读
Despite advances in surgical technology and radiation therapy,the prognosis in the patients with malignant glioma remains poor.Recent studies show that interleukin-13 receptor αt2 chain (IL-13Rα2) might be a potential biomarker and molecular target for therapy of several kinds of tumors including glioblastomas.Thus,recombinant IL-13Rα2 was used as immunogens in the B lymphocyte hybridoma technique.A total of 13 anti-IL-13Rα2 monoclonal antibodies (mAbs) with high specificity were obtained,among which 7 could be used in flow cytometry,10 could be used in Western blot while 2 could be used in immunohistochemical staining.